AROC AroCell AB

AroCell establish a Scientific Advisory Board

AroCell establish a Scientific Advisory Board

AroCell announces today that we have established a Scientific Advisory Board to support the company in its planned expansion for the coming years.

The Scientific Advisory Board (SAB) will have the objective to support the CEO and company in various matters related to AroCell’s expansion in the field of in vitro Diagnostics (IVD). The Scientific Advisory Board will focus on scientific, clinical and regulatory matters relating to AroCell’s expansion into the EU, USA and other new markets.  

The first member of the SAB is Johan von Heijne, CEO of Pharm Assist Sweden AB. Johan has long experience from various roles as CEO in companies working in the field of IVD and medical devices. His expertise in regulatory matters which he has built up over the years will be valuable for AroCell. The fact that he has a genuine and deep knowledge of AroCell as being board member since 2017 and acting CEO during part of 2018 will add further value to AroCell.

“I am very pleased that a SAB is in place at AroCell and I welcome Johan as its first member. We expect that the SAB will grow further and contribute to the company over the coming years” says Michael Brobjer, CEO of AroCell.

“AroCell’s technology and ambitious growth plan is solid and I’m eager to continue to contribute as part of the newly formed SAB” says Johan von Heijne, CEO of Pharm Assist Sweden AB.

The aim of the SAB will be to contribute in evaluating possible clinical trials to be initiated and conducted by AroCell, regulatory expertise as well as market introduction knowledge. The SAB will constitute of 3-4 members and meet regularly as needed. Additional members will be introduced during 2019.

For more information:

Michael Brobjer, CEO

Telephone: +46(0)18 50 30 20

E-mail:

information was submitted for publication through the agency of Michael Brobjer, April 17, 2019, at 08:00.

About Pharm Assist Sweden AB

Pharm Assist is a professional consultancy service company offering quality and regulatory solutions for medicinal products and medical devices. Founded in 1996, the company has assisted more than 200 pharmaceutical and medical device companies over the years.

 

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: , +46 (0)8 121 576 90.

For more information;

 

 

Attachment

EN
17/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AroCell AB

 PRESS RELEASE

Thymidine Kinase 1 can be used for early detection of therapy response...

Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based cell-loss metric after two cycles of therapy predicted the status at the operation after six cycles of chemotherapy. The metric predicted early on whether or not the chemotherapy works. The purpose with this PROMIX study is to investigate whether a cell-loss metric, defined as the ratio between s...

 PRESS RELEASE

AroCell expands with a Regulatory Affairs Director

AroCell expands with a Regulatory Affairs Director AroCell AB (publ.) announces today that Peter Löwendahl joins the management team as senior director regulatory affairs. Peter Löwendahl will lead and develop AroCell’s regulatory strategy with focus on the US market and FDA clearance of our TK 210 ELISA. Peter Löwendahl has almost 30 years of experience in quality and regulatory affairs and has previously been responsible for Quality and Regulatory affairs at Elekta AB and global regulatory responsibility for GE Healthcare's Life science division. In the last 3 years, he works mainly as a...

 PRESS RELEASE

AroCell AB (publ) Interim Report January 1st to June 30th 2019

AroCell AB (publ) Interim Report January 1st to June 30th 2019 Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as the given partner and supplier of a reliable method for measuring Thymidine kinase 1 in the blood permeates everything we do. During the quarter, we increased sales, signed more distributor agreements, signed a collaboration agreement with CLIA lab in the US and started a collaboration with the Dana Farber Cancer Institute in the USA...

 PRESS RELEASE

AroCell signs a new distributor agreement in the USA and Canada

AroCell signs a new distributor agreement in the USA and Canada AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United States and Canada. Diapharma sells tests and instrumentation for the diagnostic and research fields and provides strong technical competence and experience to ensure that their customer expectations are met. “We look forward to this new collaboration with Diapharma Group for the distribution and promotion of AroCell TK 210 ELISA in...

 PRESS RELEASE

AroCell enters a collaboration with Dana Farber Cancer Institute

AroCell enters a collaboration with Dana Farber Cancer Institute Today AroCell announces a collaboration with Dana Faber Cancer Institute to evaluate AroCell’s TK 210 ELISA assay on CDK4/6 inhibitor treated patients. The aim of the study is to examine concordance of TK 1 concentration in serum and clinical response on treatment. In the study samples will be collected from patients treated with CDK 4/6 inhibitor palbociclib throughout the course of the treatment and the concordance between AroCell’s TK 210 ELISA assay and clinical response will be evaluated. The study will include about 2...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch